This early-stage study tests a flavored, drinkable chemotherapy called VAL-413 (Orotecan) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest dose and see how the body processes…
Phase: PHASE1 • Sponsor: Valent Technologies, LLC • Aim: Disease control
Last updated May 14, 2026 12:03 UTC